杜瓦卢马布
胆道癌
吉西他滨
耐受性
顺铂
医学
肿瘤科
胆道
内科学
癌症
化疗
不利影响
无容量
免疫疗法
作者
Margherita Rimini,Lorenzo Fornaro,Mario Domenico Rizzato,Lorenzo Antonuzzo,Federico Rossari,Tomoyuki Satake,Hanne Vandeputte,Caterina Vivaldi,Tiziana Pressiani,Jessica Lucchetti,Jin Won Kim,Oluseyi Abidoye,Ilario Giovanni Rapposelli,Stefano Tamberi,Fabian Finkelmeier,Guido Giordano,Federico Nichetti,Hong Jae Chon,Chiara Braconi,Chiara Pirrone
标识
DOI：10.1016/j.ejca.2024.114199
摘要
The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combination's real-world efficacy and tolerability, we conducted a global multicenter retrospective analysis of its first-line treatment outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
浮游
吴彦祖
归尘
tuanheqi
GingerF
xxfsx
qiuqiu
义气的水蓝
且慢
Huzhu
freyaaaaa
无极微光
月子淇
从容芮
mashibeo
hanawang
franklin_fsz
地表飞猪
ZYP
美好斓
哈基米德
AbdoSpace
pual
yipmyonphu
皖公网安备34019202002308
